A randomised trial tested liposuction against standard care for lipoedema pain

Lipoedema is a chronic, painful disorder of the subcutaneous fat, affecting the legs and almost exclusively women [s1]. The standard treatment — complex decongestive therapy, meaning compression and manual lymphatic drainage — manages symptoms modestly at best [s1]. Liposuction has been offered as a more definitive option, and marketed heavily, but with little randomised evidence behind it. A multicentre trial in Germany set out to fill that gap [s1].

What the trial did

LIPLEG randomised women with stage I, II, or III lipoedema and leg pain of at least 4 on a 0-10 numeric rating scale [s1]. All received conservative therapy for up to seven months first, then were assigned 2:1 to liposuction or to continued conservative therapy, stratified by disease stage and site [s1].

The design included an unusual attempt at masking for a surgical trial: at every assessment visit, patches were applied to the legs of all patients, and patients were asked not to reveal which treatment they had received, so the assessor stayed blinded [s1]. The primary endpoint was a reduction in patient-reported leg pain of at least 2 points at 12 months, with any missing assessment counted as a failure [s1]. Counting missing data as a failure is the conservative choice: it prevents a trial from flattering the surgical arm by quietly dropping patients who did not return, and it means the reported success rate is a floor, not a best case [s1].

The seven-month run-in of conservative therapy before randomisation is worth noting too. Every participant had already tried the standard of care before being assigned, so the comparison is not surgery versus nothing but surgery versus continued conservative treatment in people for whom it had not yet resolved the pain [s1].

The trial was funded by the Federal Joint Committee, Germany — the country's public body for health-care coverage decisions, not a device or clinic company [s1]. That independent funding is the reason to take a positive surgical result seriously here: no manufacturer stood to gain from the headline.

What it found

Of 1,973 patients screened between January 19, 2021, and June 7, 2022, 453 were enrolled and 410 were randomised: 278 to liposuction and 132 to conservative therapy, mean age 42.9 years [s1].

At 12 months, 190 (68%) of the 278 patients randomised to liposuction met the pain-reduction endpoint, versus 10 (8%) of the 132 randomised to conservative therapy — an odds ratio of 26.2 (95% CI, 13.1 to 52.5; P<0.0001) [s1]. Secondary quality-of-life endpoints also improved more in the liposuction group [s1]. On the trial's own terms, surgery clearly beat continued conservative care both for pain and for how patients rated their day-to-day quality of life over the year [s1].

The harms, stated as plainly as the benefit

Surgery is not free of risk, and the trial reports the cost. Adverse events occurred in 124 (47%) of 265 patients undergoing liposuction, of whom 20 (8%) were rated serious [s1]. In the conservative group, 30 (21%) of 145 patients reported adverse events, with 5 (3%) rated serious [s1]. So the same intervention that produced the large pain benefit also roughly doubled the rate of serious adverse events relative to conservative care [s1].

How to read the very large odds ratio

An odds ratio of 26 is arresting, but part of its size comes from how little the comparator did: only 8% of the conservative group met the target [s1]. When the control response is that low, even a moderate absolute benefit produces a huge ratio. The absolute figures — 68% versus 8% meeting the endpoint — are the more honest way to hold the result, and they are still a substantial difference [s1].

The limits, stated plainly

The masking was ingenious but imperfect: patients knew whether they had undergone an operation, and the primary endpoint was patient-reported pain, which expectation can influence even when the assessor is blinded [s1]. Follow-up here is 12 months; a longer 36-month follow-up is ongoing, and durability is exactly what a one-time surgical procedure needs to prove [s1]. The trial was conducted at 11 German centres in women only, so it does not speak to other settings or to men with the condition [s1].

What to watch

The 36-month results, which will show whether the pain benefit holds, and how coverage bodies weigh a clear short-term benefit against a higher serious-harm rate [s1]. The trial is registered as LIPLEG [s2].

This article describes trial results for informational purposes only. It is not medical advice and not a recommendation about any procedure.